FDA is urging consumers to stop using and seek medical advice regarding certain hyaluronic acid products marketed for pain relief, as laboratory testing revealed hidden drug ingredients that pose severe health risks.

FDA issues 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products.

FDA warns consumers about illegal bodybuilding dietary supplement products, which often contain SARMs.

FDA and DoJ seize thousands of 7-hydroxymitragynine (7-OH) products.

FDA established a "green list" import alert to safeguard consumers from potentially dangerous GLP-1 active ingredients imported from overseas.

FDA continues to alert healthcare professionals and consumers about the risks of 7-hydroxymitragynine.

Patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies, according to FDA. 

FDA has become aware of reports of adverse events involving compounded topical finasteride products.

Summary of changes to WADA Prohibited List